Treating and Preventing Adolescent Mental Health Disorders: Treating and Preventing Adolescent Mental Health Disorders

Home > Table of Contents

Book Title: Treating and Preventing Adolescent Mental Health Disorders > pp. [792]

UNDEFINED: AUTHORS

Treating and Preventing Adolescent Mental Health Disorders

Print ISBN 9780195173642, 2005
pp. [792]

Amphetamine abuse . See also Stimulant abuse

in adolescence , 349–53

schizophrenia and , 79

Amygdala

activating factors , 176–77

in anxiety disorders , 186

developmental changes , xxix, 175

extended, in drug addiction , 375–76

Anandamide , 354

Angel dust , 371

Animal models, substance use disorders , 372–77 , 373 f, 374 f

Annenberg Public Policy Center

primary care physician survey , 580–95

school mental health professionals survey , 598–615

Annie E. Casey Foundation Blue Sky Project , 555

Anorexia nervosa . See also Eating disorders

age differences , 261

binge eating/purging subtype , 260–61 , 260 t

combination therapy , 294

comorbidity , 272–73 , 309 , 327

diagnostic criteria , 259–61 , 260 t, 262–63 , 326

diagnostic migration , 274 , 327

dieting and , 304 , 317–18

DSM-IV criteria , 259–61 , 260 t, 262–63

epidemiology , 263–72 , 275 t, 277 t, 326–27

etiology , 258–59

full-syndrome , 266 , 268

genetics , 311–12

inpatient treatment , 295–96

medical complications , 275–78 , 276 t, 327

osteopenia in , 278 , 279–80

outcome , 273–74 , 327

outpatient treatment , 295

partial-syndrome , 268

pharmacotherapy , 291–92 , 297–98

prevalence , 263–68 , 270 , 275 t, 277 t

prevention programs , 319–23

combined , 322

in high-risk populations and settings , 322

research agenda , 332

targeted , 321–22

universal , 319–21

psychosocial therapy , 284–88

evaluation , 287

randomized controlled trials , 284–87

relapse prevention , 296

refeeding in , 279

relapse prevention , 294–96 , 297–98 , 329

restricting subtype , 260 , 260 t

risk factors , 305–12 , 306 t, 330

biological , 311

eating and weight-related , 308–9

environmental , 309–11

general , 306–8

genetic , 311–12

individual , 308

weight restoration , 280–81

Antepartum depression , 32

Anticonvulsants, in schizophrenia , 126

Antidepressants . See also specific drugs

for anorexia nervosa , 292 , 298–99

for bipolar disorder , 51

for bulimia nervosa , 293–94 , 298

for generalized anxiety disorder , 195 , 197–98

heterocyclic, for major depressive disorder , 43

for major depressive disorder

in adults , 42–43

in children and adolescents , 43–47

combination and augmentation therapy , 43 , 46 , 47–48

public health advisory on , 484–85

in schizophrenia , 126

selective serotonin and noradrenaline reuptake inhibitor, for major depressive disorder , 42

selective serotonin reuptake inhibitor . See Selective serotonin reuptake inhibitors

suicidal ideation and , xxxvi, 43–44 , 435 , 485 , 618

for suicide attempters , 482–83 , 484–85

tricyclic

for generalized anxiety disorder , 195 , 197

for major depressive disorder

in adults , 43

in children and adolescents , 45 , 45 t

for panic disorder , 203

Antipsychotics . See also specific drugs

atypical

for anorexia nervosa , 292

for bipolar disorder

in adults , 50–51

with mood stabilizers , 53

for major depressive disorder , 43

for schizophrenia

acute treatment , 120 , 121t–124 t, 125

adjuncts to , 126–27

maintenance treatment , 128 , 129t–131 t

side effects , 125

Anxiety disorders , xxvii

age differences , 168

autonomic nervous system abnormalities , 177–78 , 223–24

biological correlates , 177–81

biological features , 175–76

brain developmental changes , 175–76

brain imaging , 178–79

cognitive-behavioral therapy , 185–86

developmental considerations , 186

education and skill-building , 185

exposure exercises , 185–86

history and rationale , 184–86

end p.792